Type 2 Diabetes

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

New data from the Environmental Determinants of Diabetes in the Young (TEDDY) study illuminate the environmental triggers that are thought to cause the autoimmune response leading to type 1 diabetes(T1D) and celiac disease. The data was presented in a symposium at the American Diabetes Association meeting.

New data from the Environmental Determinants of Diabetes in the Young (TEDDY) study illuminate the environmental triggers that are thought to cause the autoimmune response leading to type 1 diabetes(T1D) and celiac disease. The research, presented in a symposium at the American Diabetes Association meeting.shows that the destruction of the beta cells begins in the first two years of life.

Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.

Patients living in states that chose to expand Medicaid coverage might be seeking care earlier to prevent major leg amputation.

Results of the EXPERT study could help guide clinical decision making for GLP-1 RA-experienced patients.

Christopher Sorli, MD, describes the results of a study showing the need for simultaneous therapy rather than sequential.

Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.

Discussing the results of a phase 2 study from Diasome examining use of HDV-insulin in type 1 diabetics.

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.

Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.

Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.

Hospitalization rates decrease 52% for patients with type 1 diabetes and 47% for patients with type 2 diabetes.

The intervention model can be used to help manage a variety of chronic diseases.

Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.

Survey findings highlight the psychological and psychosocial distress related to having diabetes.

More patients achieve international time in range consensus target of greater than 70% with the Advanced system.

A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.

Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.

A study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism has found that eating a late may be a contributing factor to weight gain and hyperglycemia -- factors that may also exaccerbate heart disease.

A study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism has found that eating a late may be a contributing factor to weight gain and hyperglycemia.

According to the report, more than 20 percent of COVID patients in the ICU are patients with diabetes, presenting challenges for the clinicians managing their care.  Diabetic patients with COVID-19 in the ICU need both complex medical management of their COVID disease, along with blood sugar control to minimize complications and mortality risk- and that can require multiple patient interactions that put the provider at risk.

According to the report, more than 20 percent of COVID patients in the ICU are patients with diabetes, presenting challenges for the clinicians managing their care.  Diabetic patients with COVID-19 in the ICU need both complex medical management of their COVID disease, along with blood sugar control to minimize complications and mortality risk- and that can require multiple patient interactions that put the provider at risk.

The oral antiplatelet drug Ticagrelor (Brilinta, Astra Zeneca), was approved this week by the US Food and Drug Administration (FDA) for use in patients with coronary artery disease (CAD) who are at high risk for a first heart attack or stroke.  The change adds new treatment options to diabetic pateints at high risk for cardiac events.